Previous Issue
Volume 18, April
 
 

Pharmaceuticals, Volume 18, Issue 5 (May 2025) – 90 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
26 pages, 990 KiB  
Review
Nitropyridines in the Synthesis of Bioactive Molecules
by Alexey Starosotnikov and Maxim Bastrakov
Pharmaceuticals 2025, 18(5), 692; https://doi.org/10.3390/ph18050692 - 7 May 2025
Abstract
Pyridines are one of the most important and promising classes of N-heterocycles actively studied in modern organic and medicinal chemistry; in particular, pyridine is a privileged structural motif in drug design. From a synthetic organic chemistry perspective, nitropyridines can be considered as convenient [...] Read more.
Pyridines are one of the most important and promising classes of N-heterocycles actively studied in modern organic and medicinal chemistry; in particular, pyridine is a privileged structural motif in drug design. From a synthetic organic chemistry perspective, nitropyridines can be considered as convenient and readily available precursors for a wide range of mono- and polynuclear heterocyclic systems demonstrating diverse activities, such as antitumor, antiviral, anti-neurodegenerative, etc. This review is an analysis of the literature on the use of nitropyridines for the synthesis of biologically active compounds, covering the period from 2015 to the present. Full article
(This article belongs to the Special Issue Heterocyclic Compounds in Medicinal Chemistry, 2nd Edition)
21 pages, 2743 KiB  
Article
From Flower to Medicine: Green-Synthesized Silver Nanoparticles as Promising Antibacterial Agents
by Mohd Saeed, Reem Binsuwaidan, Nawaf Alshammari, Ahmed M. Alharbi, Nadiyah M. Alabdallahd, Nawaf A. Alotaibi, Samra Siddiqui and Safia Obaidur
Pharmaceuticals 2025, 18(5), 691; https://doi.org/10.3390/ph18050691 - 7 May 2025
Abstract
Background: Breast cancer and chronic bacterial infections are pressing global health issues, and traditional treatments are often hampered by resistance and adverse side effects. This study sought to create silver nanoparticles (AgNPs) through eco-friendly synthesis using Hibiscus rosa sinensis (HRS) flower extract and [...] Read more.
Background: Breast cancer and chronic bacterial infections are pressing global health issues, and traditional treatments are often hampered by resistance and adverse side effects. This study sought to create silver nanoparticles (AgNPs) through eco-friendly synthesis using Hibiscus rosa sinensis (HRS) flower extract and to assess their antibacterial, antibiofilm, and anticancer properties. Methods: HRS extract functioned as both a reducing and stabilizing agent in the synthesis of AgNPs. The nanoparticles were characterized using ultraviolet–visible spectroscopy (UV–Vis), Fourier-transform infrared (FTIR) spectroscopy, and transmission electron microscopy (TEM). Antibacterial and antibiofilm properties were evaluated against gram-positive (Staphylococcus aureus and Enterococcus faecalis) and gram-negative (Escherichia coli and Pseudomonas aeruginosa) bacteria using agar well diffusion and XTT reduction assays. The cytotoxic effects on MDMB-231 breast cancer cells and normal splenocytes were measured using the MTT assay, whereas fluorescence microscopy was used to observe reactive oxygen species (ROS) production, changes in mitochondrial membrane potential, and caspase-3 activation. Results: The synthesized HRS-AgNPs, primarily ranging from 10 to 50 nm, displayed a distinct surface plasmon resonance (SPR) peak at 428 nm. They exhibit notable antibacterial activity, especially against gram-positive bacteria, and effectively disrupt bacterial biofilms. Cytotoxicity evaluations showed that HRS-AgNPs decreased the viability of MDMB-231 cells in a dose-dependent manner, with minimal toxicity observed in normal splenocytes. The increase in ROS levels, reduction in mitochondrial membrane potential, and heightened caspase-3 activity collectively suggest apoptosis-driven cell death in cancer cells. Conclusions: HRS-AgNPs demonstrated dual functionality, with strong antibacterial and selective anticancer effects. Their environmentally friendly synthesis, stability, and significant biological activities suggest their potential for further development, including in vivo safety and efficacy assessments for clinical applications in treating infections and breast cancer. Full article
(This article belongs to the Section Pharmaceutical Technology)
Show Figures

Figure 1

25 pages, 5895 KiB  
Review
Exploring the Potential of s-Triazine Derivatives as Novel Antifungal Agents: A Review
by Haoyan Liao, Menglu Liu, Mengyuan Wang, Dazhi Zhang, Yumeng Hao and Fei Xie
Pharmaceuticals 2025, 18(5), 690; https://doi.org/10.3390/ph18050690 - 7 May 2025
Abstract
The growing incidence and prevalence of invasive fungal infections (IFIs) and the emergence of antimicrobial resistance compound clinical antifungal therapies. Given the significant threat posed by IFIs and the limits of the current antifungal agents, the search for novel, effective therapeutic options remains [...] Read more.
The growing incidence and prevalence of invasive fungal infections (IFIs) and the emergence of antimicrobial resistance compound clinical antifungal therapies. Given the significant threat posed by IFIs and the limits of the current antifungal agents, the search for novel, effective therapeutic options remains a compelling area of antifungal drug discovery. The s-triazine (1,3,5-triazine) scaffold, renowned for its structural versatility, ease of functionalization, and diverse biological profiles, has been extensively studied in medical chemistry. Driven by this privileged structure, several s-triazine derivatives have been synthesized through molecular hybridization and screened for their antifungal activities. Some of them demonstrated potent efficacy against pathogenic fungi, including Candida, Cryptococcus, and Aspergillus species. Structure–activity relationship (SAR) studies are also discussed whenever possible, underlying the essential substituents for their antifungal effect. This review provides a summary of recent advancements (2014–2024) in the development of antifungal agents featuring the s-triazine scaffold and highlights the antifungal activity of s-triazine derivatives, aiming to prompt further progress in this field. Full article
(This article belongs to the Collection Feature Review Collection in Medicinal Chemistry)
Show Figures

Graphical abstract

22 pages, 3787 KiB  
Article
Development of Smart pH-Sensitive Collagen-Hydroxyethylcellulose Films with Naproxen for Burn Wound Healing
by Elena-Emilia Tudoroiu, Mădălina Georgiana Albu Kaya, Cristina Elena Dinu-Pîrvu, Lăcrămioara Popa, Valentina Anuța, Mădălina Ignat, Emilia Visileanu, Durmuș Alpaslan Kaya, Răzvan Mihai Prisada and Mihaela Violeta Ghica
Pharmaceuticals 2025, 18(5), 689; https://doi.org/10.3390/ph18050689 - 7 May 2025
Abstract
Background: Developing versatile dressings that offer wound protection, maintain a moist environment, and facilitate healing represents an important therapeutic approach for burn patients. Objectives: This study presents the development of new smart pH-sensitive collagen-hydroxyethylcellulose films, incorporating naproxen and phenol red, designed [...] Read more.
Background: Developing versatile dressings that offer wound protection, maintain a moist environment, and facilitate healing represents an important therapeutic approach for burn patients. Objectives: This study presents the development of new smart pH-sensitive collagen-hydroxyethylcellulose films, incorporating naproxen and phenol red, designed to provide controlled drug release while enabling real-time pH monitoring for burn care. Methods: Biopolymeric films were prepared by the solvent-casting method using ethanol and glycerol as plasticizers. Results: Orange-colored films were thin, flexible, and easily peelable, with uniform, smooth, and nonporous morphology. Tensile strength varied from 0.61 N/mm2 to 3.33 N/mm2, indicating improved mechanical properties with increasing collagen content, while wetting analysis indicated a hydrophilic surface with contact angle values between 17.61° and 75.51°. Maximum swelling occurred at pH 7.4, ranging from 5.65 g/g to 9.20 g/g and pH 8.5, with values from 4.74 g/g to 7.92 g/g, suggesting effective exudate absorption. In vitro degradation proved structural stability maintenance for at least one day, with more than 40% weight loss. Films presented a biphasic naproxen release profile with more than 75% of the drug released after 24 h, properly managing inflammation and pain on the first-day post-burn. The pH variation mimicking the stages of the healing process demonstrated the color transition from yellow (pH 5.5) to orange (pH 7.4) and finally to bright fuchsia (pH 8.5), enabling easy visual evaluation of the wound environment. Conclusions: New multifunctional films combine diagnostic and therapeutic functions, providing a promising platform for monitoring wound healing, making them suitable for real-time wound assessment. Full article
(This article belongs to the Special Issue Development of Specific Dosage Form: Wound Dressing)
Show Figures

Figure 1

29 pages, 2438 KiB  
Article
The Impact of Hepatitis B and/or C on Liver Function and on the Response to Antiretroviral Therapy in HIV-Infected Patients: A Romanian Cohort Study
by Ruxandra-Cristina Marin, Delia Mirela Tit, Gabriela Bungău and Radu Dumitru Moleriu
Pharmaceuticals 2025, 18(5), 688; https://doi.org/10.3390/ph18050688 - 7 May 2025
Abstract
Background: Hepatitis B (HBV) and C (HCV) virus coinfections remain major contributors to liver-related morbidity and mortality among people living with HIV (PLWH). This study aimed to assess the prevalence of HBV and/or HCV coinfections in a Romanian HIV cohort and to [...] Read more.
Background: Hepatitis B (HBV) and C (HCV) virus coinfections remain major contributors to liver-related morbidity and mortality among people living with HIV (PLWH). This study aimed to assess the prevalence of HBV and/or HCV coinfections in a Romanian HIV cohort and to evaluate their impact on immunological, virological, and liver function parameters under antiretroviral therapy (ART). Methods: We retrospectively analyzed 462 HIV-infected patients (2018–2021) from the National Institute of Infectious Diseases, Bucharest, stratified into four groups: HIV mono-infection (n = 176), HIV/HBV (n = 114), HIV/HCV (n = 97), and HIV/HBV/HCV (n = 75) coinfections. Immunological (CD4 count, CD8 count, and CD4/CD8 ratio), virological (HIV-1 RNA), and hepatic parameters (ALT, AST, GGT, bilirubin, amylase, and lipase) were compared. Results: No significant differences were observed between groups regarding the immune recovery (mean CD4 count p = 0.89, HIV-RNA suppression p = 0.78). However, liver and pancreatic parameters showed statistically significant deterioration in the coinfected groups. ALT (p < 0.001), GGT (p = 0.009), total bilirubin (p = 0.011), amylase (p = 0.010), and lipase (p < 0.001) were significantly higher in the triple-infection (HIV/HBV/HCV) group compared to HIV mono-infected patients. Coinfection was also associated with a longer duration of illness (p = 0.002) and therapy (p = 0.021) and with a higher number of ART regimens used (p = 0.013). Conclusions: While HIV suppression and immune recovery were not significantly impaired by HBV/HCV coinfections, liver and pancreatic injuries were significantly more prevalent and severe in coinfected patients. Regular monitoring of hepatic function and integrated management strategies are recommended to minimize liver-related complications in this population. Full article
(This article belongs to the Special Issue HIV and Viral Hepatitis: Prevention, Treatment and Coinfection)
Show Figures

Graphical abstract

16 pages, 925 KiB  
Article
Benzyl Benzoate Isolation from Acridocarpus smeathmannii (DC.) Guill. & Perr Roots and Its Bioactivity on Human Prostate Smooth Muscle Contractions
by Oluwafemi Ezekiel Kale, Iskander Rauanov, Claudia Huber, Alexander Tamalunas, Christian G. Stief, Wolfgang Eisenreich and Martin Hennenberg
Pharmaceuticals 2025, 18(5), 687; https://doi.org/10.3390/ph18050687 - 6 May 2025
Abstract
Background/Objectives: This study is the first report on isolating a natural benzyl benzoate (nBB) from Acridocarpus smeathmannii (DC.) Guill. & Perr roots. Methods: The structure was verified using GC-MS, HPLC-UV-VIS, and two-dimensional NMR. Since it is known for its vasodilatory and anti-spasmolytic [...] Read more.
Background/Objectives: This study is the first report on isolating a natural benzyl benzoate (nBB) from Acridocarpus smeathmannii (DC.) Guill. & Perr roots. Methods: The structure was verified using GC-MS, HPLC-UV-VIS, and two-dimensional NMR. Since it is known for its vasodilatory and anti-spasmolytic actions, we investigated the biological effects of nBB on human prostate smooth tissue (rPx) obtained from a radical prostatectomy. For this purpose, rPx was incubated with nBB (0.05, 0.25, or 0.5 µM) in an organ bath, and then cumulative concentration–response curves were constructed for adrenergic agonists and electrical field stimulation (EFS). Results: Adding the various concentrations, nBB showed potential inhibition during agonist-induced contractions (0.1–100 µM). Also, neurogenic contractions of rPx by EFS (2–32 Hz) were reduced by up to 57%. Conclusions: Overall, this study reports on an efficient protocol of nBB isolation from A. smeathmannii and its contractility effects on human prostate smooth muscle. Potentially, this could contribute to the natural production of BB from A. smeathmannii species while giving it evolutionary recognition. However, since BB influences prostate smooth muscle contractility, caution in patients taking herbal supplements containing nBB is essential, as this may play a role in contributing to the symptoms of urinary tract conditions. Full article
(This article belongs to the Section Natural Products)
Show Figures

Graphical abstract

18 pages, 3597 KiB  
Article
Matrilin-2 with a K-Chitosan Scaffold Enhances Functional Recovery and Nerve Regeneration in a Segmental Rat Sciatic Nerve Injury Model
by Neill Y. Li, Brandon Vorrius, Elliott Rebello, Jonathan Ge, Amit Mohite, Zhen Qiao, Jing Ding and Qian Chen
Pharmaceuticals 2025, 18(5), 686; https://doi.org/10.3390/ph18050686 - 6 May 2025
Abstract
Background/Objectives: Previous work in our lab demonstrated that a 3D scaffold containing lysine-modified chitosan (K-chitosan) and decorated with Matrilin-2 (MATN2) enhanced Schwann cell (SC) migration and axonal outgrowth in vitro and ex vivo. This study aimed to assess the regenerative effect of this [...] Read more.
Background/Objectives: Previous work in our lab demonstrated that a 3D scaffold containing lysine-modified chitosan (K-chitosan) and decorated with Matrilin-2 (MATN2) enhanced Schwann cell (SC) migration and axonal outgrowth in vitro and ex vivo. This study aimed to assess the regenerative effect of this scaffold compared to that of a collagen conduit and an autograft using a segmental rat sciatic nerve injury model. Methods: A total of 30 Lewis Rats were assigned into three groups: an untreated collagen conduit (UC) group, a collagen conduit treated with MATN2 K-chitosan (TC) group, and a reverse autograft (RA) group. Walking force measurements, compound muscle action potential (CMAP), the wet muscle weight of the tibialis anterior and the gastrocnemius, and axonal histomorphometry were assessed. Results: The walking force and CMAP were significantly higher in the TC group compared to those in the UC group, with no significant difference between the TC and RA groups. The muscle weights were significantly greater in the TC group compared to those in the UC group but smaller than those in the RA group. The TC group experienced significantly greater axonal regeneration compared to that with the UC, and no differences were found with the RA. The TC group further demonstrated significantly greater cell counts than those in the UC group and greater affinity of the Schwann cells towards nerve reconstruction. Conclusion: The MATN2 K-chitosan scaffold significantly improved nerve regeneration and was comparable to the RA, supporting the development of a novel bio-conductive scaffold conduit. Full article
(This article belongs to the Section Biopharmaceuticals)
Show Figures

Figure 1

21 pages, 3410 KiB  
Article
Anti-Hangover and Hepatoprotective Effects of the Leaf Extract of Thunbergia laurifolia in Sprague–Dawley Rats
by Supaporn Intatham, Weerakit Taychaworaditsakul, Phraepakaporn Kunnaja, Ariyaphong Wongnoppavich, Kanjana Jaijoy, Sunee Chansakaow, Piyanuch Rojsanga and Seewaboon Sireeratawong
Pharmaceuticals 2025, 18(5), 685; https://doi.org/10.3390/ph18050685 - 5 May 2025
Abstract
Background/Objectives: The present study aims to evaluate the anti-hangover and hepatoprotective activities of the leaf extract of T. laurifolia in experimental animals. Methods: Two experiments were conducted that involved giving a single dose of the leaf extract of T. laurifolia (1, 10, or [...] Read more.
Background/Objectives: The present study aims to evaluate the anti-hangover and hepatoprotective activities of the leaf extract of T. laurifolia in experimental animals. Methods: Two experiments were conducted that involved giving a single dose of the leaf extract of T. laurifolia (1, 10, or 100 mg/kg body weight) to rats 30 min either before or after administration of 40% ethanol (5 g/kg body weight). The locomotor activity of the rats was measured before and after receiving the test substances. Blood samples were collected to determine the ethanol, acetate, and liver enzyme levels. Liver tissues were collected to evaluate alcohol-metabolizing enzymes, antioxidant enzyme activities, and antioxidant levels. Results: Administration of the leaf extract of T. laurifolia to the rats prior to ethanol increased locomotor activity and reduced blood ethanol levels. The extract also prevented changes in liver enzyme levels and demonstrated antioxidant activity by scavenging free radicals resulting from ethanol-induced oxidative stress. Conversely, rats administered the leaf extract of T. laurifolia after receiving ethanol were able to reduce the elevated liver enzyme levels back to normal levels, and probably helped to inhibit the harmful effects of free radicals by stimulating the synthesis and/or activities of antioxidant enzymes. Administration of the leaf extract of T. laurifolia either before or after ethanol exposure was able to reduce the activity of an alcohol-metabolizing enzyme as well as reduce blood acetate levels. Conclusions: In summary, receiving the leaf extract of T. laurifolia before alcohol consumption could probably help to reduce hangover symptoms and was shown to have hepatoprotective effects superior to receiving the extract after alcohol consumption. Full article
(This article belongs to the Special Issue Natural Products as an Alternative for Treatment of Human Diseases)
Show Figures

Figure 1

14 pages, 2573 KiB  
Article
In Vitro Evaluation of Drug–Drug Interaction Between Gliclazide and Antacids at the Absorption Level
by Slavica Lazarević, Srđan Kosijer, Maja Đanić, Dragana Zaklan, Bojan Stanimirov, Momir Mikov and Nebojša Pavlović
Pharmaceuticals 2025, 18(5), 684; https://doi.org/10.3390/ph18050684 - 5 May 2025
Viewed by 120
Abstract
Background: The antidiabetic drug gliclazide is often taken with antacids due to its gastrointestinal side effects. However, patients rarely report antacid use, making drug–drug interactions a potential cause of therapy failure. Therefore, this study aimed to investigate the in vitro effects of [...] Read more.
Background: The antidiabetic drug gliclazide is often taken with antacids due to its gastrointestinal side effects. However, patients rarely report antacid use, making drug–drug interactions a potential cause of therapy failure. Therefore, this study aimed to investigate the in vitro effects of various antacids on gliclazide permeability and to explore the underlying mechanisms. Methods: The permeability of gliclazide alone and in the presence of antacids (sodium bicarbonate, calcium carbonate, aluminum hydroxide, hydrotalcite and calcium carbonate/magnesium carbonate) was investigated using the parallel artificial membrane permeability assay (PAMPA) in four media (buffers pH 1.2, pH 4.5, pH 6.8 and water). The permeability coefficients were calculated, and the effect of pH on gliclazide permeability was also evaluated. Results: At simulated fasting gastric conditions (pH 1.2), groups with calcium carbonate, hydrotalcite and the combination of calcium carbonate/magnesium carbonate showed significantly higher permeability of gliclazide than the control group. At fed-state gastric conditions (pH 4.5), only hydrotalcite did not significantly change the permeability of gliclazide. Sodium bicarbonate, aluminum hydroxide and hydrotalcite significantly reduced the gliclazide permeability in comparison to the control group at pH 6.8 as a representative of fasted-state intestinal fluid. Conclusions: Antacids significantly impact the permeability of gliclazide at different pH values, potentially influencing its bioavailability. Gliclazide permeability is mainly influenced by pH-dependent ionization, though complex or salt formation may also play a role. Since both gliclazide and antacids are taken with food, and gliclazide is primarily absorbed in the small intestine, calcium- and magnesium-based antacids can be considered the most suitable choice. Full article
Show Figures

Graphical abstract

22 pages, 6216 KiB  
Article
Efficient Delivery of SARS-CoV-2 Plasmid DNA in HEK-293T Cells Using Chitosan Nanoparticles
by Citlali Cecilia Mendoza-Guevara, Alejandro Martinez-Escobar, María del Pilar Ramos-Godínez, José Esteban Muñoz-Medina and Eva Ramon-Gallegos
Pharmaceuticals 2025, 18(5), 683; https://doi.org/10.3390/ph18050683 - 5 May 2025
Viewed by 68
Abstract
Background/Objectives: Gene therapy has emerged as a promising strategy for treating a wide range of diseases. However, a major challenge remains in developing efficient and safe delivery systems for genetic material. Nanoparticles, particularly chitosan nanoparticles (CNPs), have gained significant attention as a [...] Read more.
Background/Objectives: Gene therapy has emerged as a promising strategy for treating a wide range of diseases. However, a major challenge remains in developing efficient and safe delivery systems for genetic material. Nanoparticles, particularly chitosan nanoparticles (CNPs), have gained significant attention as a potential solution. This study focuses on designing a SARS-CoV-2 plasmid DNA (pDNA) conjugated with CNPs and evaluating its in vitro delivery efficiency. Methods: The Omicron Spike DNA sequence was inserted into the pIRES2-eGFP expression vector, and CNPs were synthesized with optimized physicochemical properties to enhance stability, cellular uptake, and transfection efficiency. The conjugate was characterized using UV-Vis, FT-IR, DLS, and TEM techniques. Transfection efficiency was assessed and compared to the commercially available TurboFect reagent as a control. Results: CNPs-pDNA polyplexes with an average size of 159.0 ± 33.1 nm (TEM), a zeta potential of +19.7 ± 0.3 mV, and 100% ± 0.0 encapsulation efficiency were developed as a non-viral delivery system. CNPs efficiently serve as a delivery vehicle for the constructed pDNA without altering cell morphology, achieving transfection efficiencies of 62–74%, compared to 55–70% for TurboFect. Furthermore, RT-qPCR confirmed the expression of Spike mRNA, and Western blot assays validated the expression of Spike protein. Notably, Spike protein expression from CNPs was found to be two-fold higher than the control at 96 h post-transfection. Conclusions: These findings suggest that CNPs are a promising and versatile platform for delivering genetic material. Importantly, this study highlights the intrinsic properties of chitosan, without the use of additional ligands, as a key factor in achieving efficient gene delivery. Full article
Show Figures

Figure 1

35 pages, 19345 KiB  
Review
Natural Antidiabetic Agents: Insights into Ericaceae-Derived Phenolics and Their Role in Metabolic and Oxidative Modulation in Diabetes
by Mihaela Popescu, Kristina Radivojevic, Diana-Maria Trasca, Renata Maria Varut, Irina Enache and Andrei Osman
Pharmaceuticals 2025, 18(5), 682; https://doi.org/10.3390/ph18050682 - 4 May 2025
Viewed by 317
Abstract
Diabetes mellitus (DM) is a chronic disease with a growing prevalence worldwide, leading to severe health complications. Current treatment relies on antidiabetic medications, which may have adverse effects, highlighting the need for alternative approaches. Natural compounds, such as phenolic compounds, have shown promise [...] Read more.
Diabetes mellitus (DM) is a chronic disease with a growing prevalence worldwide, leading to severe health complications. Current treatment relies on antidiabetic medications, which may have adverse effects, highlighting the need for alternative approaches. Natural compounds, such as phenolic compounds, have shown promise in glucose modulation. The Ericaceae family includes several plants with potential antidiabetic properties. This review examines the pathophysiology of diabetes, chemical composition, and specific Ericaceae species that have demonstrated antidiabetic effects. Studies indicate that Vaccinium species and other Ericaceae plants can lower blood glucose levels and improve insulin sensitivity through mechanisms such as enzyme inhibition. These findings suggest that Ericaceae plants may serve as complementary strategies for diabetes management. Full article
(This article belongs to the Section Natural Products)
Show Figures

Figure 1

26 pages, 1707 KiB  
Review
Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology
by Iacob-Daniel Goje, Greta-Ionela Goje, Valentin Laurențiu Ordodi, Valentina Gabriela Ciobotaru, Vlad Sabin Ivan, Roxana Buzaș, Oana Tunea, Florina Bojin and Daniel-Florin Lighezan
Pharmaceuticals 2025, 18(5), 681; https://doi.org/10.3390/ph18050681 - 3 May 2025
Viewed by 134
Abstract
Cancer remains the second leading cause of death worldwide. Doxorubicin (DOX) is a cornerstone of hematologic malignancy treatment, but it is limited by its dose-dependent cardiotoxicity, leading to systolic and diastolic cardiac dysfunction and, ultimately, dilated hypokinetic cardiomyopathy. Cardio-oncology has emerged as a [...] Read more.
Cancer remains the second leading cause of death worldwide. Doxorubicin (DOX) is a cornerstone of hematologic malignancy treatment, but it is limited by its dose-dependent cardiotoxicity, leading to systolic and diastolic cardiac dysfunction and, ultimately, dilated hypokinetic cardiomyopathy. Cardio-oncology has emerged as a subspecialty addressing cardiovascular complications in cancer patients, highlighting preventive and therapeutic strategies to reduce cancer therapy-related cardiac dysfunction (CTRCD). Current approaches, including beta-blockers, renin–angiotensin system (RAS) inhibitors, and statins, offer partial cardioprotection. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for type 2 diabetes mellitus (T2DM), demonstrate pleiotropic cardioprotective effects beyond glycemic control, including reduced oxidative stress, inflammation, and myocardial remodeling. This review explores the interplay between anthracycline therapy, particularly DOX, and cardiotoxicity while evaluating SGLT2 inhibitors as novel agents in cardio-oncology. Preclinical studies suggest SGLT2 inhibitors attenuate CTRCD by preserving mitochondrial function and inhibiting apoptosis, while clinical trials highlight their efficacy in reducing heart failure (HF) hospitalizations and cardiovascular (CV) mortality. Integrating SGLT2 inhibitors into cardio-oncology protocols could revolutionize the management of CTRCD, enhancing patient outcomes in oncology and cardiovascular care. Considering the emerging evidence, SGLT2 inhibitors may provide significant benefits to patients undergoing anthracycline therapy, particularly those with elevated cardiovascular risk profiles. We recommend that future prospective, large-scale clinical trials further evaluate the efficacy and safety of these agents as cardioprotective therapy to optimize individualized treatment strategies. Full article
Show Figures

Figure 1

31 pages, 6396 KiB  
Systematic Review
Pharmacological and Non-Pharmacological Interventions for Polycystic Ovary Syndrome (PCOS) in Indian Women: A Systematic Review and Meta-Analysis
by Pratibha Maan, Rohit Gautam, Sudharsan Vasudevan, Geetha R. Menon, Amit Arora, Abilash Nair, Puthiyaveettil Khadar Jabbar and Taruna Arora
Pharmaceuticals 2025, 18(5), 680; https://doi.org/10.3390/ph18050680 - 2 May 2025
Viewed by 320
Abstract
Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in women of reproductive age. Treatment or management of this syndrome includes several pharmacological and non-pharmacological treatment approaches for different manifestations of the disease that vary with the patient’s age, symptoms, requirements, and [...] Read more.
Background: Polycystic ovary syndrome (PCOS) is an endocrine disorder prevalent in women of reproductive age. Treatment or management of this syndrome includes several pharmacological and non-pharmacological treatment approaches for different manifestations of the disease that vary with the patient’s age, symptoms, requirements, and geographical location. Objective: This systematic review aims to conduct a comprehensive and evidence-based analysis of the various available treatment options and identify knowledge gaps in PCOS management in India. Methods: A comprehensive search was conducted in PubMed, Scopus, and Embase databases from January 2010 till February 2024. We included randomized control trials (RCTs) using any pharmacological drugs (e.g., insulin sensitizers, anti-androgens, anti-obesity drugs, oral contraceptive pills, ovulation induction drugs, etc.) or non-pharmacological intervention (e.g., yoga, diet, herbal supplements, etc.) with Indian PCOS patients for improving common manifestations of PCOS and written in the English language. Studies were screened by two authors independently in a two-level process. Data extraction was also performed by two authors. Risk of bias was performed using the RoB 2 Tool. Subgroup analysis and meta-analysis were performed using the RevMan tool. Results: Thirty RCTs on pharmacological and eight on non-pharmacological interventions were included in the study. However, all the RCTs were so heterogeneous in terms of intervention used, subject recruited, and outcomes measured that meta-analysis was possible for only three subgroups (metformin vs. inositol, metformin vs. metformin+ inositol, and letrozole vs. clomiphene citrate), with only two or three studies per analysis. Most studies were single-centric and small-sized and had a high risk of bias, limiting their generalizability. Conclusions: This systematic review synthesized existing research and evaluated the effectiveness and safety of existing treatments. Limitations and gaps in the current research were identified, which may inform future research for better understanding and management of PCOS in the Indian context. Full article
(This article belongs to the Special Issue NeuroImmunoEndocrinology)
Show Figures

Graphical abstract

19 pages, 3327 KiB  
Article
Highlighting the Potential of LyeTx I, a Peptide Derived from the Venom of the Spider Lycosa erythrognatha, as a Potential Prototype for the Development of a New Antimicrobial Against Carbapenem-Resistant Klebsiella pneumoniae
by William Gustavo Lima, Amanda Souza Félix, Felipe Rocha da Silva Santos, Fernanda de Lima Tana, Amanda Neves de Souza, Rodrigo Moreira Verly and Maria Elena de Lima
Pharmaceuticals 2025, 18(5), 679; https://doi.org/10.3390/ph18050679 - 2 May 2025
Viewed by 127
Abstract
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a multidrug-resistant (MDR) gram-negative bacterium frequently involved in hospital-acquired pneumonia. The infection caused by this superbug has spread quickly in health centers worldwide, leading to high mortality rates. Due to this emerging scenario, the World Health [...] Read more.
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a multidrug-resistant (MDR) gram-negative bacterium frequently involved in hospital-acquired pneumonia. The infection caused by this superbug has spread quickly in health centers worldwide, leading to high mortality rates. Due to this emerging scenario, the World Health Organization has categorized CRKP as the highest-priority species for the development of new compounds. In this context, antimicrobial peptides (AMPs) stand out as prototypes for alternative antimicrobials against superbugs, including CRKP. Objectives: We aimed to describe the antibacterial effect of an AMP (LyeTx I), derived from the venom of the spider Lycosa erythrognatha, against CRKP in vitro and in a murine pneumonia model. Results: LyeTx I showed antibacterial effects against all the CRKP clinical isolates tested, with a minimum inhibitory concentration (MIC) range of 2–8 µM and a minimum bactericidal concentration (MBC) range of 2–16 µM. The microbial anionic membrane was the primary target of LyeTx I, which acts by displacing divalent cations bound to this structure in a manner similar to that of polymyxins. Notably, LyeTx I displayed significant lytic activity against mimetic membranes, indicating its potential to disrupt bacterial cell integrity. In in vivo assays, the LyeTx I peptide proved to be safe at a dose of 10 mg/kg. In addition, intraperitoneal use of LyeTx I reduced the bacterial load and inflammation in the lungs of animals infected with a hypervirulent strain of CRKP. Conclusions: These results indicate that LyeTx I is a potential prototype for the development of new antibacterials against MDR species, such as CRKP. Full article
(This article belongs to the Special Issue Development of Antibacterial Drugs to Combat Drug-Resistant Bacteria)
Show Figures

Graphical abstract

18 pages, 3075 KiB  
Article
Snake Venom Peptide Fractions from Bothrops jararaca and Daboia siamensis Exhibit Differential Neuroprotective Effects in Oxidative Stress-Induced Zebrafish Models
by Felipe Assumpção da Cunha e Silva, Brenda Rufino da Silva, Leticia Ribeiro de Barros, Emidio Beraldo-Neto, Adolfo Luis Almeida Maleski and Carlos Alberto-Silva
Pharmaceuticals 2025, 18(5), 678; https://doi.org/10.3390/ph18050678 - 2 May 2025
Viewed by 245
Abstract
Introduction: Snake venoms are rich sources of bioactive peptides with therapeutic potential, particularly against neurodegenerative diseases linked to oxidative stress. While the peptide fraction (<10 kDa) from Bothrops jararaca venom has shown in vitro neuroprotection, analogous fractions from related species remain unexplored in vivo. [...] Read more.
Introduction: Snake venoms are rich sources of bioactive peptides with therapeutic potential, particularly against neurodegenerative diseases linked to oxidative stress. While the peptide fraction (<10 kDa) from Bothrops jararaca venom has shown in vitro neuroprotection, analogous fractions from related species remain unexplored in vivo. Methods: This study comparatively evaluated the neuroprotective effects of two peptide fractions (pf) from Daboia siamensis (pf-Ds) and B. jararaca (pf-Bj) against H2O2-induced oxidative stress using in vitro (PC12 cells) and in vivo (zebrafish, Danio rerio) models. Results: In vitro, pf-Ds (1 µg mL−1) did not protect PC12 cells against H2O2-induced cytotoxicity, unlike previously reported effects of pf-Bj. In vivo, neither pf-Ds nor pf-Bj (1–20 µg mL−1) induced significant developmental toxicity in zebrafish larvae up to 120 h post-fertilization (hpf). The neuroprotective effects of both pf were evaluated using two experimental models: (I) Larvae at 96 hpf were exposed to either pf-Ds or pf-Bj (10 µg mL−1) for 4 h, followed by co-exposure to H2O2 (0.2 mmol L−1) for an additional 10 h to induce oxidative stress (4–20 h model); (II) Embryos at 4 hpf were treated with pf-Ds or pf-Bj (10 µg mL−1) continuously until 96 hpf, after which they were exposed to H2O2 (0.2 mmol L−1) for another 24 h (96–120 h model). In a short-term treatment model, neither fraction reversed H2O2-induced deficits in metabolism or locomotor activity. However, in a prolonged treatment model, pf-Bj significantly reversed the H2O2-induced locomotor impairment, whereas pf-Ds did not confer protection. Conclusions: These findings demonstrate, for the first time, the in vivo neuroprotective potential of pf-Bj against oxidative stress-induced behavioral deficits in zebrafish, contingent on the treatment regimen. The differential effects between pf-Ds and pf-Bj highlight species-specific venom composition and underscore the value of zebrafish for evaluating venom-derived peptides. Full article
Show Figures

Graphical abstract

11 pages, 1084 KiB  
Communication
A Successful Experience of Individualized Vancomycin Dosing in Critically Ill Patients by Using a Loading Dose and Maintenance Dose
by Jorge S. Amador, Álvaro Vega, Patricio Araos, Luis A. Quiñones and Cristián A. Amador
Pharmaceuticals 2025, 18(5), 677; https://doi.org/10.3390/ph18050677 - 2 May 2025
Viewed by 144
Abstract
Background/Objective: Vancomycin, a hydrophilic glycopeptide antibiotic with bactericidal activity against Gram-positive microorganisms, is one of the most commonly used antibiotics un the intensive care unit (ICU). Different efforts have been made to achieve a therapeutically effective plasma concentration of vancomycin by using loading [...] Read more.
Background/Objective: Vancomycin, a hydrophilic glycopeptide antibiotic with bactericidal activity against Gram-positive microorganisms, is one of the most commonly used antibiotics un the intensive care unit (ICU). Different efforts have been made to achieve a therapeutically effective plasma concentration of vancomycin by using loading and subsequent maintenance doses on an individual basis, but this remains subject to debate. Our objective was to individualize a dosage regimen in a Chilean ICU to optimize the pharmacological treatment of vancomycin by using a population pharmacokinetic model. Methods: A quantitative descriptive study was carried out in 51 patients at the adult ICU, San Borja Arriarán Clinical Hospital in Santiago, Chile. The dose of vancomycin was calculated by using a population pharmacokinetic software, the Antibiotic Kinetics®, and was subsequently validated with plasma trough levels of the drug through a patient sample. Results: The most commonly prescribed loading dose was 1500 mg and the most commonly used maintenance dose was 1000 mg, three times a day. The measured blood plasma concentrations of each patient (16.98 ± 5.423 μg/mL) were compared with the concentrations calculated through the population pharmacokinetic model (14.33 ± 4.630 μg/mL, p < 0.05). In addition, a correlation was found between the software-calculated trough concentration versus the measured trough concentration for vancomycin, with a positive correlation between both variables established (R2 = 0.65; p < 0.0001). No renal side effects were observed in the treated patient group. Conclusions: In the present study, a vancomycin dosing model for critically ill patients, based on a population pharmacokinetic model, was successfully implemented for routine clinical practice. Full article
(This article belongs to the Special Issue Population Pharmacokinetics and Pharmacogenetics)
Show Figures

Figure 1

19 pages, 1070 KiB  
Review
The Application of Glycolipid-Type Microbial Biosurfactants as Active Pharmaceutical Ingredients for the Treatment and Prevention of Cancer
by Aileen M. B. McMahon, Matthew S. Twigg, Roger Marchant and Ibrahim M. Banat
Pharmaceuticals 2025, 18(5), 676; https://doi.org/10.3390/ph18050676 - 2 May 2025
Viewed by 234
Abstract
Pharmaceutical scientists have researched the potential of secondary metabolites biosynthesized by microorganisms as active pharmaceutical ingredients (APIs) for the treatment of cancer. Ideally, these APIs should possess anticancer bioactivity that specifically targets tumor cells while having little cytotoxic effect on healthy tissue. Biosurfactants [...] Read more.
Pharmaceutical scientists have researched the potential of secondary metabolites biosynthesized by microorganisms as active pharmaceutical ingredients (APIs) for the treatment of cancer. Ideally, these APIs should possess anticancer bioactivity that specifically targets tumor cells while having little cytotoxic effect on healthy tissue. Biosurfactants are microbial secondary metabolites with surface-active properties and individual bioactivities that have the potential to either destroy cancer cells in a targeted fashion or prevent tumor cell formation. Currently, the best-studied class of microbial biosurfactants for the purpose of anticancer bioactivity is glycolipids, which contain a hydrophilic sugar moiety bonded to a hydrophobic fatty acid. Anticancer investigations are mainly carried out using in vitro models that show that compounds belonging to each of the four sub-classes of microbial glycolipid have significant anticancer bioactivity. The targeted action of this activity appears to be highly dependent on a specific congener molecular structure with nuanced alterations in structure leading to the killing of both tumor and healthy cells. This review compiles the current literature relating to glycolipid anticancer activity and provides a critical appraisal of exploiting the bioactivity of these compounds as novel anticancer agents. Finally, we propose several suggestions on how this research could be improved moving forward via method standardization. Full article
(This article belongs to the Section Biopharmaceuticals)
Show Figures

Figure 1

14 pages, 4383 KiB  
Article
Bisphosphonate-Conjugated Sitafloxacin for Treatment of Staphylococcus aureus Infection Associated with Cortical Bone Screws: Case Series in Sheep Model
by Niels Vanvelk, James Tapia-Dean, Stephan Zeiter, Karen de Mesy Bentley, Chao Xie, Frank Hal Ebetino, Shuting Sun, Jeffrey Neighbors, Edward M. Schwarz and Thomas Fintan Moriarty
Pharmaceuticals 2025, 18(5), 675; https://doi.org/10.3390/ph18050675 - 1 May 2025
Viewed by 145
Abstract
Background/Objectives: Hydroxybisphosphonate-conjugated sitafloxacin (HBCS) was developed to achieve higher antibiotic concentrations within infected bone. Small animal studies supported further development, but the feasibility of HBCS treatment in a more clinically relevant and larger animal model is unknown. Methods: In this study, [...] Read more.
Background/Objectives: Hydroxybisphosphonate-conjugated sitafloxacin (HBCS) was developed to achieve higher antibiotic concentrations within infected bone. Small animal studies supported further development, but the feasibility of HBCS treatment in a more clinically relevant and larger animal model is unknown. Methods: In this study, we present case reports on four sheep, each receiving four MRSA-contaminated tibial screws treated with different regimens of intravenous antibiotics. The first two sheep received two screws contaminated with 103 CFU and two screws contaminated with 105 CFU. Sheep 1 only received vancomycin, starting on day two. Sheep 2 received vancomycin, starting on day 2, but also received 7 doses of HBCS (2 mg/kg/48 h). The protocol for the final two sheep was revised, and both received four screws contaminated with 103 CFU, and vancomycin was started preoperatively. Sheep 3 and 4 received 7 doses (starting on day 6) and 9 doses (starting on day 2) of HBCS (4 mg/kg/48 h), respectively. Bacteriology was performed on three screws per animal. Longitudinal radiography and histology (n = 1 screw) were assessed for signs of osteolysis and reactive bone formation. Electron microscopy (EM) was performed in the first two sheep to evaluate antibiotic-induced bacterial damage. Results: All sheep tolerated HBCS infusion without clinical signs of discomfort. In addition to a high bacterial load (~104 CFU on all screws), Sheep 1 displayed extensive radiographic and histologic evidence of peri-implant osteolysis and reactive bone formation. Despite having a high bacterial load (~104 CFU on all screws), Sheep 2 displayed only mild radiographic and histologic evidence of peri-implant osteolysis and periosteal reactive bone formation. Bacteriology in Sheep 3 and 4 demonstrated near MRSA eradication (<100 CFU on 2 screws). Both sheep displayed no evidence of osteolysis or new bone formation adjacent to the screw head. EM confirmed the presence of bacteria resorbing bone and replicating in biofilm in Sheep 1, while antibiotic-killed bacteria with ruptured septal planes were seen in Sheep 2. Conclusions: This study demonstrates the feasibility of HBCS therapy in a clinically relevant animal model and provides guidance on future efficacy studies, such as the use of an inoculum of 103 CFU per screw, the initiation of antibiotic treatment commencing at the time of surgery, and the usability of antibiotic-killed bacteria within altered glycocalyx observed by TEM as a potential biomarker for HBCS efficacy. Full article
(This article belongs to the Special Issue The Pharmacology of Bisphosphonates: New Advances)
Show Figures

Graphical abstract

23 pages, 1895 KiB  
Article
Polyphenolic Composition, Mineral Profile, and Biological Activities in Different Organs of Alpine Woundwort—Insights into Antioxidant and Enzyme Inhibitory Potential
by Sabina Lachowicz-Wiśniewska, Ireneusz Ochmian, Jan Oszmiański, Rafał Wiśniewski, Małgorzata Bernatek, Paweł Rubiński and Daniela De Vita
Pharmaceuticals 2025, 18(5), 674; https://doi.org/10.3390/ph18050674 - 1 May 2025
Viewed by 199
Abstract
Background: Stachys alpina is a medicinal plant from the Lamiaceae family whose biological potential remains poorly explored. Methods: The aim of this study was to comprehensively assess the pol-yphenol profile, macro- and microelement composition, and the antioxidant, an-ti-diabetic, and anti-obesity activities of [...] Read more.
Background: Stachys alpina is a medicinal plant from the Lamiaceae family whose biological potential remains poorly explored. Methods: The aim of this study was to comprehensively assess the pol-yphenol profile, macro- and microelement composition, and the antioxidant, an-ti-diabetic, and anti-obesity activities of various plant organs (leaves, flowers, stems, and roots). Results: The leaves and flowers exhibited the highest concentration of phenolic compounds, while anthocyanins were detected exclusively in the flowers (215.05 mg/100 g dry matter (dm)) and constituted 3% of the total polyphenols. Verbas-coside and chlorogenic acid were the most abundant polyphenols, reaching 4618.88 and 3277.83 mg/ 100 g dm in the leaves. The highest ABTS and FRAP scavenging activity was observed in leaves (19.30 and 7.62 mmol TE/g dm, respectively). Principal component analysis demonstrated a strong correlation between polyphenol content and antioxidant activity (ABTS-r= 0.87 and FRAP-r = 0.90), which was further confirmed by Pearson’s correlation coefficients. The study also highlighted the significant impact of mineral composition on biological activity—calcium and magnesium dominated in stems (10,100 and 3900 mg/kg) and in roots (9200 and 3100 mg/kg), supporting the functioning of an-tioxidant enzymes, while zinc and manganese in leaves (89.43 and 155.33 mg/kg) con-tributed to intense metabolic processes. Conclusions: S. aplina could serve as a valuable source of natural antioxidants and enzyme inhibitors associated with glucose and lipid metabolism, suggesting its promising application in the prevention and management of metabolic disorders.. Full article
Show Figures

Figure 1

18 pages, 8225 KiB  
Article
Anticonvulsant Profiles of Three Hemorphin-4 Analogs with Rhodamine B in Mice
by Jana Tchekalarova, Miroslav Rangelov, Ivan Iliev, Nadezhda Todorova, Tsveta Stoyanova, Lian Nedelchev and Petar Todorov
Pharmaceuticals 2025, 18(5), 673; https://doi.org/10.3390/ph18050673 - 1 May 2025
Viewed by 95
Abstract
Background/Objectives: Hemorphins, considered to be bioactive atypical oligopeptides, are products of hemoglobin metabolism. Recently, our team reported the synthesis and characterization of three N-modified analogs of hemorphin-4 (H4) with rhodamine B (Rh). In the present study, the Rh-1, Rh-2, and Rh-3 compounds [...] Read more.
Background/Objectives: Hemorphins, considered to be bioactive atypical oligopeptides, are products of hemoglobin metabolism. Recently, our team reported the synthesis and characterization of three N-modified analogs of hemorphin-4 (H4) with rhodamine B (Rh). In the present study, the Rh-1, Rh-2, and Rh-3 compounds were intracerebroventricularly infused at doses of 1, 2.5, 5, and 10 µg/5 µL, respectively, and evaluated for their antiseizure activity in 6-Hz and maximal electroshock (MES) tests and in a pentylenetetrazol (PTZ)-induced kindling model in mice. Phenytoin and diazepam were used as the reference drugs. The role of opioid receptors (ORs) underlying their mechanism of action was also evaluated in silico and pharmacologically. Results: The three Rh-H4 compounds showed a good safety profile at a concentration of 100 µg/mL in the mouse embryonic fibroblasts. They suppressed psychomotor seizures and seizure spreading as follows: Rh-1 at doses of 5 and 10 µg/5 µL, Rh-2 at the highest dose, and Rh-3 at doses of 1–10 µg/5 µL, respectively. Administered at doses of 5 µg/5 µL (Rh-1 and Rh-3) and 10 µg/5 µL (Rh-2), the compounds suppressed clonic seizures in the kindled mice comparable to the reference drug diazepam. A combination of selective delta (DOR), kappa (KOR), and mu (MOR) OR antagonists with the highest doses of the Rh-1, Rh-2, and Rh-3 compounds was used to elucidate the possible role of ORs in the underlying mechanism related to their protective activity against seizure spread. Only the selective DOR antagonist, natrindole, suppressed the effect of the Rh-1 peptide analog on seizures. The OR antagonist naloxone prevented the antiseizure activity of Rh-1 in the kindled mice. The results of docking analysis also showed the model-specific interaction of the three Rh-H4 compounds with the OR. Conclusions: Our results suggest that the antiseizure activity of Rh-1 is mediated by the OR, and in particular by the DOR, while the mechanism underlying the antiseizure effect of Rh-3 is more complex and may involve other receptors. Full article
(This article belongs to the Special Issue Pharmacology and Mechanism of Action of Peptides in the Brain)
Show Figures

Graphical abstract

23 pages, 5623 KiB  
Article
Lanthanides-Based Nanoparticles Conjugated with Rose Bengal for FRET-Mediated X-Ray-Induced PDT
by Batoul Dhaini, Joël Daouk, Hervé Schohn, Philippe Arnoux, Valérie Jouan-Hureaux, Albert Moussaron, Agnès Hagege, Mathilde Achard, Samir Acherar, Tayssir Hamieh and Céline Frochot
Pharmaceuticals 2025, 18(5), 672; https://doi.org/10.3390/ph18050672 - 1 May 2025
Viewed by 136
Abstract
In order to find a good candidate for Förster Resonance Energy Transfer (FRET)-mediated X-ray-induced photodynamic therapy (X-PDT) for the treatment of cancer, lanthanide (Ln)-based AGuIX nanoparticles (NPs) conjugated with Rose Bengal (RB) as a photosensitizer (PS) were synthesized. X-PDT overcomes the problem of [...] Read more.
In order to find a good candidate for Förster Resonance Energy Transfer (FRET)-mediated X-ray-induced photodynamic therapy (X-PDT) for the treatment of cancer, lanthanide (Ln)-based AGuIX nanoparticles (NPs) conjugated with Rose Bengal (RB) as a photosensitizer (PS) were synthesized. X-PDT overcomes the problem of the poor penetration of visible light into tissues, which limits the efficacy of PDT in the treatment of deep-seated tumors. It is essential to optimize FRET efficiency by maximizing the overlap integral between donor emission and acceptor absorption and lengthening the duration of the donor emission. In this study, we optimized energy transfer between a scintillator (Sc) as a donor and a PS as an acceptor. Terbium (Tb) and Gadolinium (Gd) as Scs and Rose RB as a PS were chosen. The study of energy transfer between Tb, Gd and RB in solution and chelated on AGuIX NPs proved to be FRET-like. RB was conjugated directly onto AGuIX NPs (i.e., AGuIX Ln@RB), and the use of a spacer arm (i.e., AGuIX Ln@spacer arm-RB) increased FRET efficiency. Singlet oxygen production by these NPs was observed under UV–visible illumination and X-ray irradiation. The in vitro bioassay demonstrated 52% cell death of U-251MG derived from human malignant glioblastoma multiforme at a concentration of 1 μM RB after illumination and irradiation (2 Gy, 320 kV, 10 mA, 3 Gy/min at 47 cm). In addition, the RB-coupled NRP-1-targeting peptide (i.e., K(RB)DKPPR) was conjugated onto AGuIX NPs by a thiol-maleimide click chemistry reaction, and an affinity in the nM range was observed. Full article
(This article belongs to the Special Issue Photodynamic Therapy: 3rd Edition)
Show Figures

Graphical abstract

19 pages, 1602 KiB  
Review
Advances in Targeted Autophagy Modulation Strategies to Treat Cancer and Associated Treatment-Induced Cardiotoxicity
by Lauren A. Ling, Asma Boukhalfa, Andrew H. Kung, Vicky K. Yang and Howard H. Chen
Pharmaceuticals 2025, 18(5), 671; https://doi.org/10.3390/ph18050671 - 1 May 2025
Viewed by 233
Abstract
Autophagy, an evolutionarily conserved process, plays an important role in cellular homeostasis and human diseases. Cardiovascular dysfunction, which presents during cancer treatment or in cancer-free individuals years after treatment, is a growing clinical challenge. Millions of cancer survivors and patients face an unpredictable [...] Read more.
Autophagy, an evolutionarily conserved process, plays an important role in cellular homeostasis and human diseases. Cardiovascular dysfunction, which presents during cancer treatment or in cancer-free individuals years after treatment, is a growing clinical challenge. Millions of cancer survivors and patients face an unpredictable risk of developing cardiotoxicity. Cardiotoxicity due to cancer treatment, as well as cancer progression, has been linked to autophagy dysregulation. Modulating autophagy has been further proposed as a therapeutic treatment for both cancer and cardiovascular disorders. The safe and effective use of autophagy modulation as a cardioprotective strategy during cancer treatment especially requires careful consideration and experimentation to minimize the impact on cancer treatment. We focus here on recent advances in targeted autophagy modulation strategies that utilize interdisciplinary approaches in biomedical sciences and are potentially translatable to treat cardiotoxicity and improve cancer treatment outcomes. This review highlights non-small molecule autophagy modulators to enhance targeted therapy, nanomedicine for autophagy modulation and monitoring, and in vitro models and future experiments needed to bring novel autophagy discoveries from basic research to clinical translation. Full article
Show Figures

Figure 1

23 pages, 650 KiB  
Review
Exploring the Protective Effects of Traditional Antidiabetic Medications and Novel Antihyperglycemic Agents in Diabetic Rodent Models
by Cosmin Gabriel Tartau, Ianis Kevyn Stefan Boboc, Liliana Mititelu-Tartau, Maria Bogdan, Beatrice Rozalina Buca, Liliana Lacramioara Pavel and Cornelia Amalinei
Pharmaceuticals 2025, 18(5), 670; https://doi.org/10.3390/ph18050670 - 1 May 2025
Viewed by 194
Abstract
Type 2 Diabetes (T2D) is a complex metabolic disorder that affects multiple organs, leading to severe complications in the pancreas, kidneys, liver, and heart. Prolonged hyperglycemia, along with oxidative stress and chronic inflammation, plays a crucial role in accelerating tissue damage, significantly increasing [...] Read more.
Type 2 Diabetes (T2D) is a complex metabolic disorder that affects multiple organs, leading to severe complications in the pancreas, kidneys, liver, and heart. Prolonged hyperglycemia, along with oxidative stress and chronic inflammation, plays a crucial role in accelerating tissue damage, significantly increasing the risk of diabetic complications such as nephropathy, hepatopathy, and cardiovascular disease. This review evaluates the protective effects of various antidiabetic treatments on organ tissues affected by T2D, based on findings from experimental animal models. Metformin, a first-line antidiabetic agent, has been widely recognized for its ability to reduce inflammation and oxidative stress, thereby mitigating diabetes-induced organ damage. Its protective role extends beyond glucose regulation, offering benefits such as improved mitochondrial function and reduced fibrosis in affected tissues. In addition to traditional therapies, new classes of antidiabetic drugs, including sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists not only improve glycemic control but also exhibit nephroprotective and cardioprotective properties by reducing glomerular hyperfiltration, oxidative stress, and inflammation. Similarly, GLP-1 receptor agonists have been associated with reduced hepatic steatosis and enhanced cardiovascular function. Preclinical studies suggest that tirzepatide, a dual GLP-1/gastric inhibitory polypeptide receptor agonist may offer superior metabolic benefits compared to conventional GLP-1 agonists by improving β-cell function, enhancing insulin sensitivity, and reducing fatty liver progression. Despite promising preclinical results, differences between animal models and human physiology pose a challenge. Further clinical research is needed to confirm these effects and refine treatment strategies. Future T2D management aims to go beyond glycemic control, emphasizing organ protection and long-term disease prevention. Full article
(This article belongs to the Special Issue The 20th Anniversary of Pharmaceuticals—Advances in Pharmacology)
Show Figures

Figure 1

14 pages, 719 KiB  
Article
Repositioning FDA-Approved Sulfonamide-Based Drugs as Potential Carbonic Anhydrase Inhibitors in Trypanosoma cruzi: Virtual Screening and In Vitro Studies
by Eyra Ortiz-Pérez, Adriana Moreno-Rodríguez, Timoteo Delgado-Maldonado, Jessica L. Ortega-Balleza, Alonzo González-González, Alma D. Paz-González, Karina Vázquez, Guadalupe Avalos-Navarro, Simone Giovannuzzi, Claudiu T. Supuran and Gildardo Rivera
Pharmaceuticals 2025, 18(5), 669; https://doi.org/10.3390/ph18050669 - 1 May 2025
Viewed by 212
Abstract
Background/Objectives: α-carbonic anhydrase (α-TcCA) has emerged as a promising drug target in T. cruzi, the causative agent of Chagas disease in the Americas. Sulfonamides, known inhibitors of CAs, bind to the zinc ion on the enzyme’s active site. This study proposes the [...] Read more.
Background/Objectives: α-carbonic anhydrase (α-TcCA) has emerged as a promising drug target in T. cruzi, the causative agent of Chagas disease in the Americas. Sulfonamides, known inhibitors of CAs, bind to the zinc ion on the enzyme’s active site. This study proposes the repositioning of sulfonamide-based drugs to identify new trypanocidal agents. Method: Ligand-based virtual screening and molecular docking analysis were performed on FDA-approved drugs targeting α-TcCA. These compounds were evaluated in vitro and ex vivo against the A1 and NINOA strains, followed by enzymatic assays. Results: Four sulfonylureas were selected: glimepiride (Glim), acetohexamide (Ace), gliclazide (Glic), and tolbutamide (Tol). Ace and Tol had half-maximal inhibitory concentration (IC50) values similar or better than reference drugs against the NINOA strain in the epimastigote and trypomastigote stages, while Glic and Glim had the highest activity against the A1 strain (epimastigotes and amastigotes). Notably, Ace had the highest trypanocidal activity against all stages in NINOA, with IC50 values of 6.5, 46.5, and 46 μM for epimastigotes, trypomastigotes, and amastigotes, respectively. Additionally, Ace inhibited α-TcCA with KI = 5.6 μM, suggesting that its trypanocidal effect is associated to the enzyme inhibition. Conclusions: This study supports the repositioning of FDA-approved sulfonamide-based hypoglycaemic agents as trypanocidal compounds. Future studies should focus on structural modifications to improve selectivity. Integrating docking, parasitological, and enzymatic data is crucial for optimizing drug candidates for Chagas disease. Full article
(This article belongs to the Special Issue Drug Discovery and Development for Parasitic Diseases)
Show Figures

Figure 1

19 pages, 538 KiB  
Systematic Review
The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials
by Ligang Liu, Hekai Shi, Merilyn Xie, Yuxiao Sun and Milap C. Nahata
Pharmaceuticals 2025, 18(5), 668; https://doi.org/10.3390/ph18050668 - 30 Apr 2025
Viewed by 277
Abstract
Background: Obesity and type 2 diabetes (T2D) are major public health concerns. Tirzepatide has shown promise in recent clinical trials. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide in adults with obesity or type 2 diabetes, compared [...] Read more.
Background: Obesity and type 2 diabetes (T2D) are major public health concerns. Tirzepatide has shown promise in recent clinical trials. This systematic review and meta-analysis aim to evaluate the efficacy and safety of tirzepatide in adults with obesity or type 2 diabetes, compared to placebo, GLP-1 receptor agonists (GLP-1 RAs), and insulin. Method: PubMed, Embase, and the Cochrane Library were searched on 17 January 2024, focusing on phase II and III randomized controlled trials (RCTs). We included studies involving adults with T2D or obesity, comparing tirzepatide to placebo, GLP-1 RAs, or insulin. The primary outcomes were the proportion of participants achieving ≥5%, ≥10%, and ≥15% weight loss targets. Secondary outcomes included changes in body weight, waist circumference, HbA1c levels, and blood pressure. Safety outcomes focused on adverse event rates. Meta-analyses were performed, and risk of bias was assessed using the Cochrane Risk-of-Bias tool version 2. Results: Fourteen RCTs involving 14,713 patients were included. Tirzepatide significantly increased the proportion of participants achieving weight loss targets, and reduced body weight, waist circumference, HbA1c, and blood pressure versus placebo and insulin. Compared with GLP-1 RAs, tirzepatide provided comparable or better outcomes in weight loss, waist circumference, and glycemic control. The incidence of gastrointestinal adverse events was significantly higher at all doses of tirzepatide compared to placebo and insulin. When compared with GLP-1 RAs, higher doses of tirzepatide were associated with increased risk of nausea, diarrhea, and decreased appetite, but not vomiting. Conclusions: Tirzepatide is an effective option for managing weight and improving metabolic outcomes in patients with T2D or obesity. However, it is associated with an increased risk of gastrointestinal adverse events, especially at higher doses. Therefore, close monitoring should be considered in clinical practice. Registration: PROSPERO CRD42021283449. Full article
(This article belongs to the Section Pharmacology)
Show Figures

Figure 1

23 pages, 2798 KiB  
Article
The Cordyceps Genus as a Potential Source of Bioactive Compounds for Adjuvant Cancer Therapy: A Network Pharmacology Approach
by Jose Luis Gonzalez-Llerena, Daniela Treviño-Almaguer, Jesus Alejandro Leal-Mendez, Gael Garcia-Valdez, Arely Guadalupe Balderas-Moreno, Michel Stéphane Heya, Isaias Balderas-Renteria, María del Rayo Camacho-Corona and Bryan Alejandro Espinosa-Rodriguez
Pharmaceuticals 2025, 18(5), 667; https://doi.org/10.3390/ph18050667 - 30 Apr 2025
Viewed by 164
Abstract
Background/Objectives: Cancer remains one of the leading causes of mortality globally, underscoring the need for novel therapeutic strategies capable of targeting multiple molecular pathways simultaneously. Natural products, particularly fungal-derived metabolites from the genus Cordyceps, represent promising candidates due to their diverse biological [...] Read more.
Background/Objectives: Cancer remains one of the leading causes of mortality globally, underscoring the need for novel therapeutic strategies capable of targeting multiple molecular pathways simultaneously. Natural products, particularly fungal-derived metabolites from the genus Cordyceps, represent promising candidates due to their diverse biological activities. Although previous studies have indicated the anticancer potential of Cordyceps species, systematic characterization of their molecular targets has been limited. This study aimed to comprehensively identify and evaluate Cordyceps metabolites as potential multitarget anticancer agents through a network pharmacology approach. Methods: A total of 129 metabolites previously reported in the literature from polar aqueous, alcoholic, and non-polar extracts of Cordyceps were compiled and chemically classified using ChemMine tools. Structure-based target prediction and pathway enrichment analyses were performed to investigate their potential biological targets. Predicted molecular targets were cross-referenced with differentially expressed genes in breast, colorectal, and lung cancers to identify hub proteins. Molecular docking simulations were conducted to assess binding affinities of metabolites to key oncogenic targets, and SwissADME was utilized for pharmacokinetic profiling. Results: The analysis revealed that Cordyceps metabolites targeted critical oncogenic pathways, including cell cycle regulation, DNA replication, and apoptosis. Hub proteins such as TYMS, AURKA, and CDK1 were identified as primary targets. Docking simulations highlighted metabolites such as cordycepsidone A, jiangxienone, and flazin, demonstrating binding affinities comparable or superior to clinically used inhibitors. Pharmacokinetic profiling identified several metabolites with favorable drug-like properties, supporting their potential as lead compounds. Conclusions:Cordyceps extracts contain structurally diverse metabolites capable of modulating multiple cancer-relevant molecular targets, providing a robust foundation for their development into multitarget anticancer therapies. This integrative network pharmacology approach underscores the potential of fungal metabolites in oncology drug discovery. Full article
(This article belongs to the Special Issue Adjuvant Therapies for Cancer Treatment: 2nd Edition)
Show Figures

Graphical abstract

22 pages, 8027 KiB  
Article
Natural Killer Cell Activation Signature Identifies Cyclin B1/CDK1 as a Druggable Target to Overcome Natural Killer Cell Dysfunction and Tumor Invasiveness in Melanoma
by Linbin Chen, Wanqian Liao, Jing Huang, Qiuyue Ding, Junwan Wu, Qiong Zhang, Ya Ding, Dandan Li, Jingjing Li, Xizhi Wen and Xiaoshi Zhang
Pharmaceuticals 2025, 18(5), 666; https://doi.org/10.3390/ph18050666 - 30 Apr 2025
Viewed by 74
Abstract
Background/Objectives: Natural killer (NK) cells play a crucial role in immune surveillance against melanoma, yet they frequently exhibit dysfunction in the tumor microenvironment. This study aims to establish an NK cell activation-related prognostic signature and identify potential druggable targets to overcome NK cell [...] Read more.
Background/Objectives: Natural killer (NK) cells play a crucial role in immune surveillance against melanoma, yet they frequently exhibit dysfunction in the tumor microenvironment. This study aims to establish an NK cell activation-related prognostic signature and identify potential druggable targets to overcome NK cell dysfunction. Methods: A prognostic signature was developed using the TCGA-SKCM cohort and validated across independent datasets. NK cell activation and cytotoxicity were evaluated in melanoma-NK-92MI co-culture systems via flow cytometry. Mechanistic studies employed Western blotting, co-immunoprecipitation, ELISA, and qRT-PCR. Single-cell RNA-seq data were used to analyze cell–cell communication. Results: A four-gene NK cell activation signature was identified and validated for prognostic significance across five independent melanoma datasets. Among the identified genes, cyclin B1 (CCNB1) emerged as a novel therapeutic target for overcoming NK cell resistance. In vivo, pharmacological inhibition of the CCNB1/Cyclin-dependent kinase 1 (CDK1) complex with RO-3306 significantly suppressed melanoma growth by enhancing NK cell infiltration and IFN-γ production. In vitro, CCNB1 knockdown in melanoma cells augmented NK-92MI activation, as evidenced by increased expression of CD69, CD107a, IFN-γ, and NKG2D, thereby improving NK cell-mediated cytotoxicity. Mechanistically, in melanoma cells, the CCNB1/CDK1 complex phosphorylates STAT3, activating the IL-6/STAT3 positive feedback loop, which upregulates PD-L1 and enables resistance to NK cell-mediated cytotoxicity. Beyond its role in immune evasion, CCNB1 also promoted melanoma invasiveness by inducing epithelial–mesenchymal transition (EMT) through the TGF-β-SMAD2/3 signaling. Conclusions: This study establishes CCNB1/CDK1 as a novel immunotherapeutic target and uncovers a new role for CDK1 inhibitors in enhancing NK cell function and suppressing melanoma progression. Full article
(This article belongs to the Topic Kinases in Cancer and Other Diseases, 2nd Edition)
Show Figures

Figure 1

42 pages, 789 KiB  
Review
New Agents in the Treatment of Psychiatric Disorders: What Innovations and in What Areas of Psychopathology?
by Paola Bozzatello, Roberta Novelli, Rebecca Schisano, Claudio Brasso, Paola Rocca and Silvio Bellino
Pharmaceuticals 2025, 18(5), 665; https://doi.org/10.3390/ph18050665 - 30 Apr 2025
Viewed by 223
Abstract
Psychiatric disorders are a major cause of illness in the world. Unfortunately, many patients are resistant to treatment and present serious complications. Schizophrenia is refractory to treatment in about one-third of patients. Antidepressants are effective in about half of patients. Suicidal ideation is [...] Read more.
Psychiatric disorders are a major cause of illness in the world. Unfortunately, many patients are resistant to treatment and present serious complications. Schizophrenia is refractory to treatment in about one-third of patients. Antidepressants are effective in about half of patients. Suicidal ideation is an increasing issue in patients with mixed features in bipolar disorder (BD). Therefore, there is a need to develop and test new drugs or new indications of available medications for the treatment of psychiatric disorders through evidence-based investigations. This narrative review aims to present the molecules approved by the main drug agencies, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), from 2018 to date, along with new indications and new formulations of existing medications. We searched PubMed for new drugs approved for schizophrenia, BD, major depressive disorder (MDD), anxiety disorders, and obsessive-compulsive disorder (OCD). We evaluated their clinical benefits, safety, and tolerability profiles. Finally, we considered studies on the main molecules that have shown initial evidence of efficacy and are in the process of obtaining approval. Our search suggested that a new antipsychotic, lumateperone, and two drug combinations, olanzapine/samidorphan (OLZ/SAM) and xanomeline/trospium (KarXT), were approved for schizophrenia. In addition, some new methods of administration—monthly risperidone administration, subcutaneous risperidone administration, and transdermal asenapine administration—obtained approval from the main drug agencies. Lumateperone and OLZ/SAM were also approved in BD. Esketamine, a compound that modulates glutamatergic transmission, was approved to treat treatment-resistant depression and acute suicidal ideation. The dextromethorphan/bupropion combination was approved for MDD. Two new agents, brexanolone and zuranolone, were approved for treatment of postpartum depression. On the other hand, no new drugs received approval for anxiety disorders or OCD. In summary, some new psychotropic medications have been developed, in particular with the aim to improve the symptoms of resistant patients and to decrease the incidence of adverse effects. It is necessary to continue testing the effectiveness of new compounds in methodologically rigorous studies. Full article
(This article belongs to the Special Issue Recent Advances in Psychopharmacology)
Show Figures

Figure 1

15 pages, 4463 KiB  
Article
Norfloxacin Derivative with Carbazole at C-7 FQB-1 Induces Cytotoxic, Antiproliferative, and Antitumor Effects in an Experimental Lung Carcinoma Model
by Alondra Bocanegra-Zapata, Hiram Hernández-López, Socorro Leyva-Ramos, Rodolfo Daniel Cervantes-Villagrana, Marisol Galván-Valencia, L. Angel Veyna-Hurtado, Norma Guadalupe Ramírez Tovar, Damaris Albores-García, Juan Armando Flores de la Torre and Alberto Rafael Cervantes-Villagrana
Pharmaceuticals 2025, 18(5), 664; https://doi.org/10.3390/ph18050664 - 30 Apr 2025
Viewed by 793
Abstract
Background: Cancer remains a leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO), lung cancer is the most prevalent type of cancer among both men and women. Despite the various pharmacological and biological treatments available for lung cancer, [...] Read more.
Background: Cancer remains a leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO), lung cancer is the most prevalent type of cancer among both men and women. Despite the various pharmacological and biological treatments available for lung cancer, their effectiveness has often fallen short, and the side effects can be severe. Therefore, there is an ongoing need to identify and develop novel compounds with enhanced anti-tumor efficacy and improved safety profiles. Research has shown that fluoroquinolone derivatives exhibit a broad cytotoxic spectrum comparable to other drugs used in clinical chemotherapy. Objective: The aim of this work was to synthesize and evaluate the cytotoxic, anti-proliferative, and anti-tumor effects of FQB-1, a novel fluoroquinolone derivative. Results: In silico molecular docking analysis demonstrated a strong interaction between FQB-1 and human topoisomerase, with a binding affinity score of –9.8 kcal/mol. In vitro cytotoxicity and anti-proliferative assays were conducted using the Lewis Lung Carcinoma (LLC) cell line. FQB-1 was tested at concentrations of 2.5, 5.0, 25.0, 50.0, 100.0, and 150.0 µg/mL. Significant cytotoxic and anti-proliferative effects were observed at concentrations of 50–150 µg/mL after 24 h of treatment. To evaluate FQB-1′s efficacy in vivo, a syngeneic tumor model was established in C57BL/6 mice. Treatment with FQB-1 (100 mg/kg) resulted in a marked reduction in tumor volume compared to the untreated control group. Histopathological analysis of tumor tissues from treated animals revealed a decrease in mitotic index and an increase in necrotic regions, indicating compromised tumor viability. Conclusions: FQB-1 exhibits cytotoxic and anti-proliferative effects and can reduce tumor growth while compromising tumor viability. Full article
(This article belongs to the Special Issue Fluoroquinolones)
Show Figures

Graphical abstract

17 pages, 2797 KiB  
Article
Investigation of the Anti-Lung Cancer Mechanisms of Taraxacum officinale Based on Network Pharmacology and Multidimensional Experimental Validation
by Jianing Liu, Hailing Yang, Ran Liu, Dongjin Sun, Yongbao Liu, Jing Lu, Jinbiao Liu and Junrui Lu
Pharmaceuticals 2025, 18(5), 663; https://doi.org/10.3390/ph18050663 - 30 Apr 2025
Viewed by 120
Abstract
Background:Taraxacum officinale(commonly known as dandelion) is a medicinal and edible plant, with the entire plant being used for therapeutic purposes. Studies have demonstrated that dandelion exhibits inhibitory effects against various types of cancer. However, research on its potential for lung cancer [...] Read more.
Background:Taraxacum officinale(commonly known as dandelion) is a medicinal and edible plant, with the entire plant being used for therapeutic purposes. Studies have demonstrated that dandelion exhibits inhibitory effects against various types of cancer. However, research on its potential for lung cancer (LC) treatment is limited, and the specific compounds responsible for its anticancer effects, as well as the underlying mechanisms, remain unclear. Methods: This study aimed to elucidate the underlying pharmacological mechanisms by which dandelion exerts therapeutic effects against LC. Initially, active compounds of dandelion and their corresponding targets were retrieved from public databases. Subsequently, network pharmacology approaches were applied to identify LC-associated disease targets. By integrating drug-specific targets and disease-related targets, a comprehensive dandelion–lung cancer interaction network was established. Protein–protein interaction (PPI) analyses and functional enrichment studies were further performed to uncover potential molecular mechanisms. Additionally, molecular docking and molecular dynamics (MD) simulations were conducted to evaluate binding interactions between critical active constituents and core targets. To experimentally validate these findings, in vitro cellular assays combined with scanning electron microscopy (SEM) were employed to investigate the anticancer effects of taraxasterol, a key bioactive sterol compound isolated from dandelion, on LC cells. Results: Our analyses identified 58 active compounds in dandelion linked to 614 potential targets, of which 228 targets were associated with LC. The PPI network highlighted 16 core targets, notably TP53, CASP3 and EGFR. Functional enrichment analysis suggested that dandelion might exert its anticancer effects by modulating the tumor microenvironment through the regulation of these critical targets. Molecular docking results demonstrated stable binding interactions between major active compounds and the identified core targets. Furthermore, the anticancer activity of taraxasterol was experimentally validated through in vitro assays and SEM-based morphological assessments, confirming its inhibitory effects on A549 lung cancer cells. Conclusions: Collectively, our findings reveal a multi-targeted therapeutic mechanism of dandelion against LC and support its potential development as a novel natural candidate for lung cancer treatment. Full article
(This article belongs to the Special Issue Adjuvant Therapies for Cancer Treatment)
Show Figures

Figure 1

Previous Issue
Back to TopTop